by Factor Xa inhibitors have become an important class of anticoagulant medicines used to help prevent and manage dangerous blood clots. Among the different therapies available, apixaban, rivaroxaban, and edoxaban are widely recognized as direct oral Factor Xa inhibitors. Research from Towards Healthcare shows that the apixaban segment held a significant share of the oral Factor Xa inhibitors market, while rivaroxaban is also expected to see strong growth.
This naturally raises an important question: Who manufactures the leading Factor Xa inhibitor available in the United States?
What Are Factor Xa Inhibitors?
Factor Xa inhibitors are anticoagulant medicines that target Factor Xa, an important component of the blood-clotting pathway. By inhibiting Factor Xa, these medicines help prevent the formation of thrombin and, ultimately, blood clots.
According to Towards Healthcare, commonly used direct Factor Xa inhibitors include:
- Apixaban
- Rivaroxaban
- Edoxaban
These medicines are used across conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE).
Which Factor Xa Inhibitor Leads the Market?
Among oral Factor Xa inhibitors, apixaban held a considerable revenue share in 2025, accounting for approximately 40% of the oral Factor Xa inhibitors market, according to Towards Healthcare. The research describes apixaban as a potent and highly selective oral Factor Xa inhibitor.
This makes apixaban an important answer when discussing the leading Factor Xa inhibitor in the current market.
Towards Healthcare estimates that the global oral Factor Xa inhibitors market was valued at USD 24.2 billion in 2025 and is projected to reach approximately USD 43.75 billion by 2035, expanding at a 6.1% CAGR from 2026 to 2035.
For the broader Factor Xa inhibitors market, Towards Healthcare estimates growth from USD 22.1 billion in 2023 to USD 41.52 billion by 2034, representing a CAGR of 5.9% from 2024 to 2034.
The growth is expected to be supported by increasing cardiovascular disease prevalence, continued development of DOACs, broader clinical applications, and growing pharmaceutical investment.
Who Manufactures Apixaban?
Pfizer and Bristol Myers Squibb are associated with the development and commercialization of Eliquis (apixaban), one of the leading Factor Xa inhibitor brands.
Towards Healthcare lists both Pfizer and Bristol Myers Squibb among the major companies participating in the Factor Xa inhibitors market. It also identifies Pfizer among the leading companies in the broader oral Factor Xa inhibitor landscape.
Eliquis has become an important oral anticoagulant for patients requiring prevention of stroke and systemic embolism associated with atrial fibrillation, as well as treatment and prevention of DVT and PE.
What About Rivaroxaban?
Another major Factor Xa inhibitor is rivaroxaban, marketed under the brand Xarelto.
Towards Healthcare identifies Janssen Pharmaceuticals and Bayer among the key companies in the Factor Xa inhibitor market. Rivaroxaban is also expected to experience significant growth within the oral Factor Xa inhibitor segment.
The competitive landscape has also expanded with generic versions. Towards Healthcare reports that the U.S. FDA approved the first generic direct oral anticoagulant rivaroxaban 2.5 mg tablets in March 2025, prepared by Lupin and Taro.
In addition, Alembic Pharmaceuticals received final U.S. FDA approval for its rivaroxaban tablets in multiple strengths in May 2025, while Aurobindo Pharma received approval to manufacture and market rivaroxaban 2.5 mg tablets.
Why Is the United States an Important Market?
The United States represents a particularly important market for Factor Xa inhibitors. Towards Healthcare reports that North America held a major revenue share, with the U.S. representing the dominant contributor because of its advanced healthcare infrastructure, pharmaceutical industry, research capabilities, and significant cardiovascular disease burden.
The increasing prevalence of cardiovascular conditions, atrial fibrillation, stroke, DVT, and PE continues to support demand for anticoagulant therapies.
Towards Healthcare also highlights atrial fibrillation as a major application segment for Factor Xa inhibitors. As the number of patients with atrial fibrillation increases, preventing stroke safely and effectively remains a significant clinical priority.
What Is Driving Demand for Factor Xa Inhibitors?
Several factors are supporting continued adoption of these medicines.
Growing Cardiovascular Disease Burden
Cardiovascular diseases remain a major driver of anticoagulant demand. Factor Xa inhibitors provide an oral option for patients who require anticoagulation for conditions associated with clot formation.
Shift Toward Direct Oral Anticoagulants
Towards Healthcare describes direct oral anticoagulants (DOACs) as an important future direction for the Factor Xa inhibitor industry. These medicines offer a different approach from traditional vitamin K antagonists such as warfarin and have expanded treatment options for patients.
Convenience of Oral Administration
Oral Factor Xa inhibitors can be taken as tablets or capsules without requiring administration by a healthcare professional. This convenience is one factor supporting their demand.
Growing Generic Competition
The U.S. market is also seeing increased competition from generic rivaroxaban manufacturers. Approvals involving companies such as Lupin, Taro, Alembic Pharmaceuticals, and Aurobindo Pharma demonstrate how the competitive environment is expanding beyond the original branded products.
Who Are the Major Companies in the Factor Xa Inhibitor Industry?
Towards Healthcare identifies a broad competitive landscape that includes:
- Pfizer
- Bristol Myers Squibb
- Daiichi Sankyo
- Bayer
- Janssen Pharmaceuticals
- Viatris
- Lupin
- Dr. Reddy’s Laboratories
- GlaxoSmithKline
- Accord Healthcare
- Apotex
- Zydus
- Eugia Pharma
- Hansoh Pharma
- Shanghai Huilun Pharmaceutical
These companies participate in different areas of the Factor Xa inhibitor ecosystem, including branded products, generic medicines, manufacturing, and pharmaceutical development.
About Us
Pharma Geek is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
